Pomilla Kumar, MD
Family Medicine · Bettendorf, IANPI 1568431880
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,653 and has fallen 72.9% since, to $447 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$877
- AbbVie$781
- Novo Nordisk$658
- Otsuka America Pharmaceutical, Inc.$572
- Pfizer$567
- Lilly USA, LLC$366
- plus $4K from 49 others
What the payments were for
- Food & beverage$7,924100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,931 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 567 | $177,970 |
| OzempicSemaglutide | 71 | $77,210 |
| TrulicityDulaglutide | 90 | $48,290 |
| JardianceEmpagliflozin | 122 | $42,942 |
| JanuviaSitagliptin Phosphate | 75 | $29,018 |
| FarxigaDapagliflozin Propanediol | 48 | $28,901 |
| XareltoRivaroxaban | 90 | $27,827 |
| Spiriva RespimatTiotropium Bromide | 26 | $19,070 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $16,671 |
| TradjentaLinagliptin | 18 | $14,554 |
| ElmironPentosan Polysulfate Sodium | 33 | $14,396 |
| Sevelamer Carbonate | 51 | $14,054 |
| Potassium Chloride | 573 | $13,697 |
| Atorvastatin Calcium | 1,119 | $12,649 |
| Gabapentin | 769 | $12,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $567 | $177,970567 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat, Stiolto Respimat | $195 | $89,301192 claims |
| Novo NordiskOzempic, Levemir | $658 | $82,83589 claims |
| Lilly USA, LLCTrulicity | $366 | $48,29090 claims |
| AstraZenecaFarxiga, Symbicort | $877 | $36,52881 claims |
| MerckJanuvia, Dulera | $74 | $35,50794 claims |
| GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta | $246 | $32,89979 claims |
| Johnson & JohnsonXarelto | $239 | $27,82790 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $9,89242 claims |
| AbbVieLinzess | $781 | $6,21111 claims |
| Sanofi-aventis U.S. LLCLantus | $162 | $5,21964 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Bettendorf
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.